Sahin et al. (2000) have recently investigated the expression of seven CT genes (MAGE-3, NY-ESO-1, HOM-MEL-40/SSX-2, SSX-1, SSX-4, HOM-TES-14/SCP-1, and HOM-TES-85) in a series of human brain tumour specimens, and concluded that a majority of oligoastrocytomas and astrocytomas might be amenable to specific immunotherapeutic interventions, although the identification of additional tumour-specific antigens frequently expressed in gliomas should allow for the development of widely applicable polyvalent glioma vaccines [30]. The gene discussed is MAGEA3; the disease is central nervous system cancer.